Walgreens and BARDA Collaborate on $100M Decentralized Clinical Trials Initiative

Partnership Details:
Walgreens and the Biomedical Advanced Research and Development Authority (BARDA) have entered into a five-year partnership valued at up to $100 million.

Purpose:
The partnership aims to expand and enhance decentralized clinical trials through the Decentralized Clinical Operations for Healthcare and Research program.

Impact:
This collaboration is expected to make clinical trials more accessible and efficient, potentially accelerating the development of new treatments and therapies.

Date:
The partnership was announced on August 20, 2024.